162 related articles for article (PubMed ID: 37603217)
21. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
Bunglawala F; Rajoli RKR; Mirochnick M; Owen A; Siccardi M
J Antimicrob Chemother; 2020 Mar; 75(3):640-647. PubMed ID: 31860112
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
23. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.
Jacobs TG; Mumbiro V; Cassia U; Zimba K; Nalwanga D; Ballesteros A; Domínguez-Rodríguez S; Tagarro A; Madrid L; Mutata C; Chitsamatanga M; Bwakura-Dangarembizi M; Passanduca A; Buck WC; Nduna B; Chabala C; Najjingo E; Musiime V; Moraleda C; Colbers A; Mujuru HA; Rojo P; Burger DM;
Clin Infect Dis; 2024 Mar; 78(3):702-710. PubMed ID: 37882611
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.
Zhang J; Hayes S; Sadler BM; Minto I; Brandt J; Piscitelli S; Min S; Song IH
Br J Clin Pharmacol; 2015 Sep; 80(3):502-14. PubMed ID: 25819132
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
MacBrayne CE; Castillo-Mancilla J; Burton JR; MaWhinney S; Wagner CB; Micke K; Fey J; Huntley RT; Larson B; Bushman LR; Kiser JJ
J Antimicrob Chemother; 2018 Jan; 73(1):156-159. PubMed ID: 29029135
[TBL] [Abstract][Full Text] [Related]
27. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
28. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
29. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
30. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
Pene Dumitrescu T; Joshi SR; Xu J; Greene TJ; Johnson M; Butcher L; Zimmerman E; Webster L; Pham TT; Lataillade M; Min S
Br J Clin Pharmacol; 2021 Sep; 87(9):3501-3507. PubMed ID: 33533507
[TBL] [Abstract][Full Text] [Related]
31. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology of HIV integrase inhibitors.
Adams JL; Greener BN; Kashuba AD
Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
[TBL] [Abstract][Full Text] [Related]
33. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
[TBL] [Abstract][Full Text] [Related]
34. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
36. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
[TBL] [Abstract][Full Text] [Related]
37. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
38. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
Dickinson L; Walimbwa S; Singh Y; Kaboggoza J; Kintu K; Sihlangu M; Coombs JA; Malaba TR; Byamugisha J; Pertinez H; Amara A; Gini J; Else L; Heiberg C; Hodel EM; Reynolds H; Myer L; Waitt C; Khoo S; Lamorde M; Orrell C;
Clin Infect Dis; 2021 Sep; 73(5):e1200-e1207. PubMed ID: 33346335
[TBL] [Abstract][Full Text] [Related]
39. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
Bevers LAH; Waalewijn H; Szubert AJ; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Burger DM; Gibb DM; Colbers A
Clin Infect Dis; 2023 Nov; 77(9):1312-1317. PubMed ID: 37280040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
